Display options
Cite
Benralizumab (Fasenra) for Severe Eosinophilic Asthma. JAMA. 2018;319(14):1501-1502doi: 10.1001/jama.2018.3609.
(2018). Benralizumab (Fasenra) for Severe Eosinophilic Asthma. JAMA, 319(14), 1501-1502. https://doi.org/10.1001/jama.2018.3609
"Benralizumab (Fasenra) for Severe Eosinophilic Asthma." JAMA vol. 319,14 (2018): 1501-1502. doi: https://doi.org/10.1001/jama.2018.3609
Benralizumab (Fasenra) for Severe Eosinophilic Asthma. JAMA. 2018 Apr 10;319(14):1501-1502. doi: 10.1001/jama.2018.3609. PMID: 29634828.
Copy Download .nbib Format: NLM
Share it on

JAMA. 2018 Apr 10;319(14):1501-1502. doi: 10.1001/jama.2018.3609.

Benralizumab (Fasenra) for Severe Eosinophilic Asthma.

JAMA

[No authors listed]

PMID: 29634828 DOI: 10.1001/jama.2018.3609

[No abstract available.]

Publication Types